TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from ImmunoPrecise Antibodies ( (IPA) ).
ImmunoPrecise Antibodies Ltd. has sold its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio for $12 million USD. This strategic divestiture allows IPA to streamline its operations, strengthen its balance sheet, and focus on its AI-based SaaS platform, LENSai™, which aids in biologics discovery. The transaction supports IPA’s investment in scientific platforms and data-driven technologies, enhancing its industry positioning and providing value to investors.
The most recent analyst rating on (IPA) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on ImmunoPrecise Antibodies stock, see the IPA Stock Forecast page.
Spark’s Take on IPA Stock
According to Spark, TipRanks’ AI Analyst, IPA is a Neutral.
The overall score reflects strong recent operational improvements and strategic positioning as highlighted in the earnings call. However, persistent profitability challenges and negative cash flows weigh down the financial performance score. Technical indicators and ongoing strategic initiatives add moderately positive support.
To see Spark’s full report on IPA stock, click here.
More about ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd. is a biotherapeutics company focused on the discovery and development of next-generation biologics. The company combines scientific expertise with proprietary technologies, such as its LENSai™ platform, to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research.
Average Trading Volume: 2,463,858
Technical Sentiment Signal: Buy
Current Market Cap: $83.54M
For an in-depth examination of IPA stock, go to TipRanks’ Overview page.